Role of c-MET in Upper Aerodigestive Malignancies — From Biology to Novel Therapies

2005 ◽  
Vol 24 (3) ◽  
pp. 149-162 ◽  
Author(s):  
Sascha Dietrich ◽  
Radha Uppalapati ◽  
Tanguy Y. Seiwert ◽  
Patrick C. Ma
Keyword(s):  
Novel Therapies

Chemo- and Optogenetic Strategies for the Elucidation of Pain Pathways

2019 ◽  
pp. 816-832 ◽  
Author(s):  
Sascha R. A. Alles ◽  
Anne-Marie Malfait ◽  
Richard J. Miller
Keyword(s):  
Chronic Pain ◽  
Pain Response ◽  
Conscious Perception ◽  
Novel Therapies ◽  
The Past ◽  
Nociceptive Pathways ◽  
Pain Pathways ◽  
Technical Advances ◽  
The Brain

Pain is not a simple phenomenon and, beyond its conscious perception, involves circuitry that allows the brain to provide an affective context for nociception, which can influence mood and memory. In the past decade, neurobiological techniques have been developed that allow investigators to elucidate the importance of particular groups of neurons in different aspects of the pain response, something that may have important translational implications for the development of novel therapies. Chemo- and optogenetics represent two of the most important technical advances of recent times for gaining understanding of physiological circuitry underlying complex behaviors. The use of these techniques for teasing out the role of neurons and glia in nociceptive pathways is a rapidly growing area of research. The major findings of studies focused on understanding circuitry involved in different aspects of nociception and pain are highlighted in this article. In addition, attention is drawn to the possibility of modification of chemo- and optogenetic techniques for use as potential therapies for treatment of chronic pain disorders in human patients.

scholarly journals Physiology to the Pleiotropic Role of RNAs: Prospecting Novel Therapies

2014 ◽  
Vol 2014 ◽  
pp. 1-1
Author(s):  
Maria Chiara Maiuri ◽  
Daniela De Stefano ◽  
Ammad Ahmad Farooqi
Keyword(s):  
Novel Therapies

scholarly journals From Interconnection between Genes and Microenvironment to Novel Immunotherapeutic Approaches in Upper Gastro-Intestinal Cancers—A Multidisciplinary Perspective

Cancers ◽  
2020 ◽  
Vol 12 (8) ◽  
pp. 2105
Author(s):  
Giulia Accordino ◽  
Sara Lettieri ◽  
Chandra Bortolotto ◽  
Silvia Benvenuti ◽  
Anna Gallotti ◽  
...  
Keyword(s):  
Unmet Need ◽  
Predictive Biomarkers ◽  
Standard Of Care ◽  
Integrated Approach ◽  
Point Of View ◽  
Novel Therapies ◽  
Car T ◽  
Treatment Data ◽  
Multidisciplinary Perspective

Despite the progress during the last decade, patients with advanced gastric and esophageal cancers still have poor prognosis. Finding optimal therapeutic strategies represents an unmet need in this field. Several prognostic and predictive factors have been evaluated and may guide clinicians in choosing a tailored treatment. Data from large studies investigating the role of immunotherapy in gastrointestinal cancers are promising but further investigations are necessary to better select those patients who can mostly benefit from these novel therapies. This review will focus on the treatment of metastatic esophageal and gastric cancer. We will review the standard of care and the role of novel therapies such as immunotherapies and CAR-T. Moreover, we will focus on the analysis of potential predictive biomarkers such as Modify as: Microsatellite Instability (MSI) and PD-L1, which may lead to treatment personalization and improved treatment outcomes. A multidisciplinary point of view is mandatory to generate an integrated approach to properly exploit these novel antiproliferative agents.

scholarly journals 410 The role of NK cells in WASp related cancer and eczema: Studies on the pathogenesis and possible novel therapies

2016 ◽  
Vol 136 (9) ◽  
pp. S230
Author(s):  
H. Brauner ◽  
J. Kritikou ◽  
C. Dahlberg ◽  
M. Baptista ◽  
A. Wagner ◽  
...  
Keyword(s):  
Nk Cells ◽  
Novel Therapies

Autologous Stem-Cell Transplantation for Multiple Myeloma in the Era of Novel Therapies

2020 ◽  
Vol 16 (2) ◽  
pp. 56-66 ◽  
Author(s):  
Ricardo D. Parrondo ◽  
Sikander Ailawadhi ◽  
Taimur Sher ◽  
Asher A. Chanan-Khan ◽  
Vivek Roy
Keyword(s):  
Multiple Myeloma ◽  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Autologous Stem Cell Transplantation ◽  
Residual Disease ◽  
Proteasome Inhibitors ◽  
Novel Therapies ◽  
Immunomodulatory Agents

Despite the evolution of the therapeutic arsenal for the treatment of multiple myeloma (MM) over the past decade, autologous stem-cell transplantation (ASCT) remains an integral part of the treatment of patients with both newly diagnosed and relapsed MM. The advent of novel therapies, such as immunomodulatory agents, proteasome inhibitors, and monoclonal antibodies, has led to unprecedented levels of deep hematologic responses. Nonetheless, studies show that ASCT has an additive effect leading to additional deepening of responses. As the therapeutic agents for MM continue to evolve, the timing, duration, and sequence of their use in combination with ASCT will be crucial to understand to obtain the deepest response and survival benefit for patients with MM. This review aims to discuss the role of ASCT for the management of MM, with a particular focus on the role of ASCT in the context of novel therapies and minimal residual disease.

Sign in / Sign up

Export Citation Format

Share Document